Story type: Industry

People living with inflammatory bowel disease (IBD) have new hope, with clinical trials beginning for a breakthrough treatment for one of the most difficult to treat conditions associated with the disease.…  Read more

Hudson Institute of Medical Research has been recognised as a leader in RNA based medicine, with new federal government funding set to accelerate the search for new and better treatments.…  Read more

Hudson Institute’s reputation as a leader in inflammation research has been boosted by the appointment of two specialists in the field.…  Read more

Hudson Institute partner BiomeBank has secured a multimillion-dollar Federal Government grant that will turbocharge the development and production of microbiome-based therapeutics.…  Read more

A new class of anti-inflammatory drug is opening a world of possibilities for treating everything from neurological diseases to cancers.…  Read more

Exciting new treatments for unmet medical needs including ovarian cancer have been awarded significant funding from Australia’s national biotechnology incubator, CUREator.…  Read more

Congratulations to Professor Ron Firestein, who was announced this week as Deputy Director of Hudson Institute of Medical Research.…  Read more

The CEO of Hudson Institute of Medical Research, Professor Elizabeth Hartland, has been appointed chair of the Victorian chapter of AAMRI, the Association of Australian Medical Research Institutes.…  Read more

A new anti-viral drug to target the cause of viral lung infections and the infection itself could be a game-changer in treating severe influenza.…  Read more

RNA technology developed by Hudson Institute of Medical Research with the potential to limit inflammatory side-effects of RNA therapeutics such as mRNA vaccines, is the subject of a new licensing deal.…  Read more